{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:32:36Z","timestamp":1792801956241,"version":"4.5.0"},"reference-count":53,"publisher":"BMJ","issue":"5","license":[{"start":{"date-parts":[[2022,5,24]],"date-time":"2022-05-24T00:00:00Z","timestamp":1653350400000},"content-version":"unspecified","delay-in-days":23,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2022,4,14]]},"published-print":{"date-parts":[[2022,5]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Therapeutic cancer vaccines represent a promising approach to improve clinical outcomes with immune checkpoint inhibition. UV1 is a second generation telomerase-targeting therapeutic cancer vaccine being investigated across multiple indications. Although telomerase is a near-universal tumor target, different treatment combinations applied across indications may affect the induced immune response. Three phase I\/IIa clinical trials covering malignant melanoma, non-small cell lung cancer, and prostate cancer have been completed, with patients in follow-up for up to 8 years.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>52 patients were enrolled across the three trials. UV1 was given as monotherapy in the lung cancer trial and concurrent with combined androgen blockade in the prostate cancer trial. In the melanoma study, patients initiated ipilimumab treatment 1 week after the first vaccine dose. Patients were followed for UV1-specific immune responses at frequent intervals during vaccination, and every 6 months for up to 8 years in a follow-up period. Phenotypic and functional characterizations were performed on patient-derived vaccine-specific T cell responses.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In total, 78.4% of treated patients mounted a measurable vaccine-induced T cell response in blood. The immune responses in the malignant melanoma trial, where UV1 was combined with ipilimumab, occurred more rapidly and frequently than in the lung and prostate cancer trials. In several patients, immune responses peaked years after their last vaccination. An in-depth characterization of the immune responses revealed polyfunctional CD4+ T cells producing interferon-\u03b3 and tumor necrosis factor-\u03b1 on interaction with their antigen.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Long-term immunomonitoring of patients showed highly dynamic and persistent telomerase peptide-specific immune responses lasting up to 7.5 years after the initial vaccination, suggesting a plausible functional role of these T cells in long-term survivors. The superior immune response kinetics observed in the melanoma study substantiate the rationale for future combinatorial treatment strategies with UV1 vaccination and checkpoint inhibition for rapid and frequent induction of anti-telomerase immune responses in patients with cancer.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jitc-2021-004345","type":"journal-article","created":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T11:55:51Z","timestamp":1653479751000},"page":"e004345","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":40,"title":["Durable and dynamic hTERT immune responses following vaccination with the long-peptide cancer vaccine UV1: long-term follow-up of three phase I clinical trials"],"prefix":"10.1136","volume":"10","clinical-trial-number":[{"clinical-trial-number":"nct02275416","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01789099","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01784913","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04742075","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04382664","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04300244","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0235-1184","authenticated-orcid":false,"given":"Espen Basmo","family":"Ellingsen","sequence":"first","affiliation":[{"name":"Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway"},{"name":"Faculty of Medicine, University of Oslo, Oslo, Norway"},{"name":"Ultimovacs ASA, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elin","family":"Aamdal","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Oslo, Oslo, Norway"},{"name":"Department of Oncology, Oslo University Hospital, Oslo, Norway"},{"name":"Department of Oncology, Akershus University Hospital, L\u00f8renskog, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tormod","family":"Guren","sequence":"additional","affiliation":[{"name":"Department of Oncology, Oslo University Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Lilleby","sequence":"additional","affiliation":[{"name":"Department of Oncology, Oslo University Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paal F","family":"Brunsvig","sequence":"additional","affiliation":[{"name":"Department of Oncology, Oslo University Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara M","family":"Mangsbo","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Science for Life Laboratory, Uppsala University, Uppsala, Sweden"},{"name":"Ultimovacs AB, Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steinar","family":"Aamdal","sequence":"additional","affiliation":[{"name":"Ultimovacs ASA, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eivind","family":"Hovig","sequence":"additional","affiliation":[{"name":"Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway"},{"name":"Centre for Bioinformatics, Department of Informatics, University of Oslo, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Mensali","sequence":"additional","affiliation":[{"name":"Department of Cellular Therapy, Oslo University Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustav","family":"Gaudernack","sequence":"additional","affiliation":[{"name":"Ultimovacs ASA, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Else Marit","family":"Inderberg","sequence":"additional","affiliation":[{"name":"Department of Cellular Therapy, Oslo University Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,5,25]]},"reference":[{"key":"2025100314224177000_10.5.e004345.1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2017.434"},{"key":"2025100314224177000_10.5.e004345.2","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med Overseas Ed"},{"key":"2025100314224177000_10.5.e004345.3","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70236-0"},{"key":"2025100314224177000_10.5.e004345.4","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/s41586-020-2537-9","article-title":"An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma","volume":"585","author":"Sahin","year":"2020","journal-title":"Nature"},{"key":"2025100314224177000_10.5.e004345.5","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.cell.2020.08.053","article-title":"A phase Ib trial of personalized neoantigen therapy plus anti-PD-1 in patients with advanced melanoma, non-small cell lung cancer, or bladder cancer","volume":"183","author":"Ott","year":"2020","journal-title":"Cell"},{"key":"2025100314224177000_10.5.e004345.6","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1038\/s41591-021-01544-x","article-title":"A phase 1\/2 trial of an immune-modulatory vaccine against IDO\/PD-L1 in combination with nivolumab in metastatic melanoma","volume":"27","author":"Kjeldsen","year":"2021","journal-title":"Nat Med"},{"key":"2025100314224177000_10.5.e004345.7","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(97)00062-2"},{"key":"2025100314224177000_10.5.e004345.8","doi-asserted-by":"publisher","DOI":"10.1126\/science.7605428"},{"key":"2025100314224177000_10.5.e004345.9","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2012.441"},{"key":"2025100314224177000_10.5.e004345.10","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1002\/1873-3468.13084","article-title":"Essential roles of telomerase reverse transcriptase hTERT in cancer stemness and metastasis","volume":"592","author":"Hannen","year":"2018","journal-title":"FEBS Lett"},{"key":"2025100314224177000_10.5.e004345.11","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.182407599"},{"key":"2025100314224177000_10.5.e004345.12","doi-asserted-by":"publisher","DOI":"10.1097\/00000658-199911000-00015"},{"key":"2025100314224177000_10.5.e004345.13","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2012.602"},{"key":"2025100314224177000_10.5.e004345.14","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/89.24.1874"},{"key":"2025100314224177000_10.5.e004345.15","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/s41416-019-0531-5","article-title":"Distinct prognostic value of circulating anti-telomerase CD4+ Th1 immunity and exhausted PD-1+\/TIM-3+ T cells in lung cancer","volume":"121","author":"Laheurte","year":"2019","journal-title":"Br J Cancer"},{"key":"2025100314224177000_10.5.e004345.16","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.jid.2021.07.160","article-title":"Naturally occurring telomerase-specific CD4 T-cell immunity in melanoma","volume":"142","author":"Nardin","year":"2022","journal-title":"J Invest Dermatol"},{"key":"2025100314224177000_10.5.e004345.17","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12061687","article-title":"Telomerase and CD4 T cell immunity in cancer","volume":"12","author":"Dosset","year":"2020","journal-title":"Cancers"},{"key":"2025100314224177000_10.5.e004345.18","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.682492","article-title":"Telomerase as a target for therapeutic cancer vaccines and considerations for optimizing their clinical potential","volume":"12","author":"Ellingsen","year":"2021","journal-title":"Front Immunol"},{"key":"2025100314224177000_10.5.e004345.19","doi-asserted-by":"publisher","DOI":"10.4161\/onci.20426"},{"key":"2025100314224177000_10.5.e004345.20","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-011-0991-9"},{"key":"2025100314224177000_10.5.e004345.21","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201343324"},{"key":"2025100314224177000_10.5.e004345.22","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/j.cell.2016.01.049","article-title":"The basis of oncoimmunology","volume":"164","author":"Palucka","year":"2016","journal-title":"Cell"},{"key":"2025100314224177000_10.5.e004345.23","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-018-0044-0"},{"key":"2025100314224177000_10.5.e004345.24","doi-asserted-by":"publisher","DOI":"10.1038\/nature14426"},{"key":"2025100314224177000_10.5.e004345.25","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1171447","article-title":"HLA class II antigen-processing pathway in tumors: molecular defects and clinical relevance","volume":"6","author":"Seliger","year":"2017","journal-title":"Oncoimmunology"},{"key":"2025100314224177000_10.5.e004345.26","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abe3348"},{"key":"2025100314224177000_10.5.e004345.27","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1900778"},{"key":"2025100314224177000_10.5.e004345.28","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.ymthe.2020.11.019","article-title":"Targeting telomerase with an HLA class II-restricted TCR for cancer immunotherapy","volume":"29","author":"Dillard","year":"2021","journal-title":"Mol Ther"},{"key":"2025100314224177000_10.5.e004345.29","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.663865","article-title":"Combining a Universal Telomerase Based Cancer Vaccine With Ipilimumab in Patients With Metastatic Melanoma - Five-Year Follow Up of a Phase I\/IIa Trial","volume":"12","author":"Aamdal","year":"2021","journal-title":"Front Immunol"},{"key":"2025100314224177000_10.5.e004345.30","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.572172","article-title":"Long-term outcomes of a phase I study with UV1, a second generation telomerase based vaccine, in patients with advanced non-small cell lung cancer","volume":"11","author":"Brunsvig","year":"2020","journal-title":"Front Immunol"},{"key":"2025100314224177000_10.5.e004345.31","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s00262-017-1994-y","article-title":"Phase I\/IIa clinical trial of a novel hTERT peptide vaccine in men with metastatic hormone-naive prostate cancer","volume":"66","author":"Lilleby","year":"2017","journal-title":"Cancer Immunol Immunother"},{"key":"2025100314224177000_10.5.e004345.32","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0215(19970904)72:5<784::AID-IJC14>3.0.CO;2-9"},{"key":"2025100314224177000_10.5.e004345.33","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-0039.1992.tb01951.x"},{"key":"2025100314224177000_10.5.e004345.34","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.16.1.201"},{"key":"2025100314224177000_10.5.e004345.35","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa042980"},{"key":"2025100314224177000_10.5.e004345.36","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0508124102"},{"key":"2025100314224177000_10.5.e004345.37","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0701009104"},{"key":"2025100314224177000_10.5.e004345.38","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4333"},{"key":"2025100314224177000_10.5.e004345.39","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms3185"},{"key":"2025100314224177000_10.5.e004345.40","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0367"},{"key":"2025100314224177000_10.5.e004345.41","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-3372"},{"key":"2025100314224177000_10.5.e004345.42","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aad5659"},{"key":"2025100314224177000_10.5.e004345.43","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-5048"},{"key":"2025100314224177000_10.5.e004345.44","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-2931"},{"key":"2025100314224177000_10.5.e004345.45","doi-asserted-by":"publisher","DOI":"10.1126\/science.abd1329"},{"key":"2025100314224177000_10.5.e004345.46","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2008.04.001"},{"key":"2025100314224177000_10.5.e004345.47","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20052246"},{"key":"2025100314224177000_10.5.e004345.48","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-009-0670-2"},{"key":"2025100314224177000_10.5.e004345.49","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41417-020-0183-x","article-title":"Revisiting the role of CD4+ T cells in cancer immunotherapy-new insights into old paradigms","volume":"28","author":"Tay","year":"2021","journal-title":"Cancer Gene Ther"},{"key":"2025100314224177000_10.5.e004345.50","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-16-1219"},{"key":"2025100314224177000_10.5.e004345.51","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41586-018-0792-9","article-title":"Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial","volume":"565","author":"Keskin","year":"2019","journal-title":"Nature"},{"key":"2025100314224177000_10.5.e004345.52","doi-asserted-by":"publisher","DOI":"10.1038\/nature22991"},{"key":"2025100314224177000_10.5.e004345.53","doi-asserted-by":"publisher","DOI":"10.1038\/nature23003"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2021-004345","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T21:22:49Z","timestamp":1759526569000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2021-004345"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":53,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,5,25]]},"published-print":{"date-parts":[[2022,5]]}},"alternative-id":["10.1136\/jitc-2021-004345"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2021-004345","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5]]}}}